Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

BACKGROUND: Somatostatin analogues effectively control flushing and diarrhoea in patients with the carcinoid syndrome. The octapeptide lanreotide is available in slow release form, which could eliminate the necessity of twice a day injections as with octreotide. PATIENTS AND METHODS: 39 patients wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 1996-08, Vol.39 (2), p.279-283
Hauptverfasser:	Ruszniewski, P, Ducreux, M, Chayvialle, J A, Blumberg, J, Cloarec, D, Michel, H, Raymond, J M, Dupas, J L, Gouerou, H, Jian, R, Genestin, E, Bernades, P, Rougier, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences Biomarkers, Tumor Chemotherapy Diarrhea - drug therapy Diarrhea - etiology Female Flushing - drug therapy Flushing - etiology Humans Hydroxyindoleacetic Acid - urine Male Malignant Carcinoid Syndrome - complications Medical sciences Middle Aged Peptides, Cyclic Pharmacology. Drug treatments Prospective Studies Somatostatin - analogs & derivatives Somatostatin - therapeutic use Tomography, X-Ray Computed
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!